# Etanercept for the Treatment of Lupus Nephritis

> **NCT00447265** · PHASE2 · TERMINATED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 1 (actual)

## Conditions studied

- Lupus Nephritis

## Interventions

- **DRUG:** Etanercept
- **DRUG:** Lupus Treatment- Standard of Care
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00447265
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The perceived risk-benefit ratio for individuals with early active RA
- **Last updated:** 2013-02-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00447265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00447265, "Etanercept for the Treatment of Lupus Nephritis". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00447265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*